TCM
VNDA icon

Teza Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Teza Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,544
Closed -$155K – 624
2020
Q2 		$155K Sell
13,544
-2,200
-14% -$24.9K 0.03% 513
2020
Q1 		$163K Sell
15,744
-9,266
-37% -$115K 0.52% 87
2019
Q4 		$410K Sell
25,010
-7,950
-24% -$120K 0.11% 337
2019
Q3 		$438K Buy
+32,960
New +$459K 0.11% 293

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Teza Capital Management's VNDA Position: Q3 2020 in Review

Teza Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2020, closing a stake of 13,544 shares — an estimated $155K sold.

Teza Capital Management first reported a position in VNDA in Q3 2019 and held it in 4 quarters. The position peaked at $438K in Q3 2019. 164 funds tracked by Wall St. Rank hold VNDA as of Q3 2020.

  • Teza Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Teza Capital Management sold 13,544 Vanda Pharmaceuticals shares in Q3 2020, an estimated $155K.
  • Teza Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Teza Capital Management's Vanda Pharmaceuticals position peaked at $438K in Q3 2019.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2020.

Based on Teza Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.